Drugs / C2C\_ASC
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05602116 | Jun 2023 → Jun 2024 | autism spectrum disorder, bowel dysfunction, inflammatory bowel disease | Cell to Cure ApS | Completed | No outcome recorded |
| Phase 1 | NCT05595681 | Dec 2022 → Nov 2025 | ulcer of lower limbs | Cell to Cure ApS | Terminated | No outcome recorded Stop: Enrollment |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | C2C\_ASC | “The investigational product is a C2C\_ASC cell product (Cell2Cure®, Cell2Cure ApS, Denmark).” NCT05595681 ↗1“The Investigational Product is a C2C\_ASC cell product (Cell2Cure®, Cell2Cure Aps, Denmark).” NCT05602116 ↗ |
| Known as | Cell2Cure | “The Investigational Product is a C2C\_ASC cell product (Cell2Cure®, Cell2Cure Aps, Denmark).” NCT05602116 ↗1“The investigational product is a C2C\_ASC cell product (Cell2Cure®, Cell2Cure ApS, Denmark).” NCT05595681 ↗ |
| Modality | Cell therapy | “C2C\_ASC is an advanced therapy investigational medicinal product (ATIMP) manufactured from abdominal adipose tissue derived mesenchymal stromal cells (ASC) from healthy donors.” NCT05602116 ↗ |
| Route | Subcutaneous | “will be injected into the subcutaneous dermo-epidermal junction” NCT05595681 ↗ |